ROLE OF SILDENAFIL AS A FACTOR MODULATING SKELETAL MUSCLE CONTRACTILITY IN CASES OF INDUCED DIABETIC RATS

Thesis

Submitted for fulfillment of master degree in Medical Physiology

By

Nour EL-din Bashir Salem (M.B.B.Ch.)

Supervised by

Prof. Dr. Akef Abdel Halim Khowailed

Professor of Physiology
Faculty of Medicine
Cairo University

Dr. Zeinab Abd El-Wahab

Ass. Professor of Physiology
Faculty of Medicine
Cairo University

Prof. Dr. Olfat Shaker

Professor of Biochemistry
Faculty of Medicine
Cairo University

Faculty of Medicine Cairo University 2012 Role Of Sildenafil as a Factor Modulating Skeletal Muscle Contractility In Cases Of Induced Diabetic Rats / Nour EL-ddin Bashir Salem, visitor demonstrator of physiology, faculty of Medicine, Cairo University. Supervisors: Prof. Dr. Akef Abdel Halim Khowailed, Professor of Physiology, Faculty of Medicine, Cairo University; Dr. Zeinab Abd El-Wahab, Ass. Professor of Physiology, Faculty of Medicine, Cairo University, Prof. Dr. Olfat Shaker; Professor of Biochemistry Faculty of Medicine, Cairo University.

ABSTRACT

Aim of work: This study was designed to evaluate the effect of sildenafil citrate on skeletal muscle contractility in type 2 diabetic rats.

Materials and methods: Diabetes was induced by feeding rats with a high fat diet (HFD) for 2 weeks followed by an intraperitoneal injection of streptozotocin (35 mg/kg body weight). The considered rats were divided into four groups containing ten animals for each, group1: normal control, group 2: diabetic group, group 3: diabetic treated with 5mg/kg/day sildenafil for 4 weeks and group 4: diabetic treated with 10mg/kg/day sildenafil for 4 weeks. By the end of the experimental period rats were sacrificed, blood samples were taken and serum was isolated for estimation of glucose, insulin, TNF-α, IL-1β, IL-6 and lipid profile parameters. In addition, diaphragm contractility was determined in the studied groups.

Results:

In the diabetic group, levels of glucose, TNF- α , IL-1 β , IL-6, glycosylated hemoglobin, HOMA-IR, total cholesterol, triglycerides, LDL-cholesterol and vLDL-cholesterol were significantly increased, while contractility index, serum HDL-cholesterol and insulin levels were decreased. Both doses of sildenafil significantly reversed these alterations. Moreover, supplementation with either dose significantly ameliorated the diminished diaphragm contractility.

Conclusion: The current study showed that sildenafil citrate has pronounced useful effects on skeletal muscle contractility via ameliorating the deteriorated metabolic parameters in type 2 diabetic rats.

Key words:

sildenafil, insulin resistance, muscle contractility index, oxidative stress.

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to my supervisor, **Dr. AKEF KHOWAILED**, Professor of Physiology, Faculty of Medicine, Cairo University, for his support, feedback, and guidance on this research as well as giving me various opportunities that enriched my growth as a student, a researcher, and a scientist to be. I am grateful to him in every possible way.

It is difficult to translate my gratitude and thanks to Dr. Olfat Shaker, Professor of the Biochemistry, Faculty of Medicine, Cairo University, Dr. Zeinab Abd-ElWahab, Ass. Professor of Physiology, Faculty of Medicine, Cairo University, for her continuous encouragement and valuable support throughout the present study.

Last but not least, I wish to express my deep thanks and gratitude to my family for constant help and encouragement.

Contents

List of abbreviations	I
List of tables	IV
List of figures	V
Introduction	1
Aim of work	3
Review of literature	
Chapter 1: Diabetes Mellitus	4
Chapter 2: Nitric Oxide	30
Chapter 3: Sildenafil Citrate	41
Materials and methods	50
Results	69
Discussion	95
Summary	116
Conclusion	120
Recommendations	
References	122
Arabic summary	

List of Abbreviations

ADA	American Diabetes Association
AMPK	AMP activated protein kinase
ANOVA	Analysis of variance
ATGL	Adipose triglyceride lipase
BH ₄	Tetrahydrobiopterin
CaM	Calmoduline
cGMP	Cyclic guanosine monophosphate
CMV	Cytomegalovirus
CNG	Cyclic nucleotide-gated channels
CRP	C-reactive protein
DAG	Diacylglycerol
DCCT	Diabetes Control and Complications Trial
DGC	Dystrophin glycoprotein complex
DM	Diabetic mellitus
DTNB	Dithiobis-2-nitrobenzoic acid
ED	Erectile dysfunction
EDRF	Endothelium-derived relaxing factor
EDTA	Ethylenediamine tetraacetic acid
EMEA	European Agency for the Evaluation of Medicinal
	Products
eNOS	Endothelial nitric oxide synthase
ERK	Extracellular signal regulated kinase
FAD	Flavin adenine dinucleotide
FDA	Food and Drug Administration
FFA	Free fatty acids
FMN	Flavin mononucleotide
GAD	Glutamic acid decarboxylase
GK	Glucokinase
GLUT	Glucose transporter
GPO	Glycerol-3-phosphate oxidase
GP _x	Glutathione peroxidase
GSH	Glutathione
GTP	Guanosine triphosphate

HDL	High density lipoprotein
HFD	High fat diet
HK	Hexokinase
HOMA-IR	Homeostasis model of insulin resistance
HSL	Hormone-sensitive lipase
ICE	Interleukin-1 converting enzyme
IDDM	Insulin dependent diabetes mellitus
IDF	International Diabetes Federation
IL	Interleukin
iNOS	Inducible nitric oxide synthase
IR	Insulin receptor
IRS	Insulin receptor substrates
LDL	Low-density lipoprotein
LPL	Lipoprotein lipase
LPS	Lipopolysaccharide
LSD	Least significant difference
MAPK	Mitogen-activated protein kinase
MDA	Malondialdehyde
MHC	Major histocompatibility complex
MRDM	Malnutrition related Diabetes Mellitus
MS	Metabolic Syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NANC	Nonadrenergic noncholinergic
NIDDM	Non-insulin dependent diabetes mellitus
nNOS	Neuronal nitric oxide synthase
NO	Nitric oxide
NOS	Nitric oxide synthase
OD	Optical Denisty
PC	Phosphatidylcholine
PPAR	Peroxisome proliferator activated receptor
PE	Phosphatidylethanoloamine
PGC	PPARγ coactivator
PI3K	Phosphatidylinositol 3-kinase
PKB	Protein kinase B
PKC	Protein kinase C
PLC	Phospholipase C

PS	Phosphatidylserine
POLG	Polymerase DNA gamma
PTP	Tyrosine phosphatase
ROIs	Reactive oxygen intermediates
ROS	Reactive Oxygen Species
sGC	Soluble guanylate cyclase
SH2	Src-homology- 2
STZ	Streptozotocin
T2DM	Type 2 diabetes mellitus
SOCS	Suppressors of cytokine signaling proteins
SOD	Superoxide dismutase
SR	Soluble receptor
SSBP	Single strand binding protein
TBARS	Thiobarbituric acid reacting substance
TCA	Trichloroacetic acid
TNF-α	Tumor necrosis factor-alpha
VLDL	Very low-density lipoprotein
VSMC	Vascular smooth muscle cells
WHO	World Health Organization

List of tables

		Page
	Fasting and postprandial serum glucose levels	70
Table 1	of normal, diabetic and diabetic rats treated with	
	sildenafil	
	Blood glycosylaed hemoglobin (HbA1c%),	73
Table 2	serum insulin level and HOMA-IR of normal,	
I able 2	diabetic control and diabetic rats treated with	
	sildenafil.	
Table 3	Liver and muscle glycogen levels of normal,	77
Table 3	diabetic and diabetic rats treated with sildenafil.	
Table 4	Lipid profile of normal, diabetic and diabetic rats	81
I able 4	treated with sildenafil.	
Table 5	Serum TNF- α , IL-1 β and IL-6 of normal, diabetic	84
Table 3	control and diabetic rats treated with sildenafil.	
Table 6	Liver MDA and GSH of normal, diabetic and	87
I able 0	diabetic rats treated with sildenafil.	
Table 7	Liver SOD and GPx of normal, diabetic and	90
Table 1	diabetic rats treated with sildenafil.	
	Effect of sildenafil on skeletal muscle	93
Table 8	contractility of normal, diabetic and diabetic rats	
	treated with sildenafil.	

List of figures

		Page
Figure 1	Schematic presentation of insulin signaling pathways	14
Figure 2	Beneficial and detrimental effects of NO.	33
Figure 3	Synthesis reaction of nitric oxide.	37
Figure 4	Effect of sildenafil on fasting and postprandial	71
, and the second	blood glucose levels of normal, diabetic control and diabetic treated rats.	
Figure 5	Effect of sildenafil on serum insulin concentration.	74
Figure 6	Effect of sildenafil on HOMA-IR.	75
Figure 7	Effect of sildenafil on HbA1c%.	75
Figure 8	Effect of sildenafil on liver glycogen content.	78
Figure 9	Effect of sildenafil on muscle glycogen content.	78
Figure 10	Effect of sildenafil on lipid profile.	82
Figure 11	Serum TNF-α, IL-1β and IL-6 of normal, diabetic control and diabetic rats treated with sildenafil.	85
Figure 12	Liver MDA of normal, diabetic control and diabetic treated rats.	88
Figure 13	Liver GSH of normal, diabetic control and diabetic treated rats.	88
Figure 14	Liver SOD of normal, diabetic control and diabetic treated rats.	91

Figure 15:	Liver GPx of normal, diabetic control and	91
	diabetic treated rats.	
Figure 16	Diaphragm contractility index of normal, diabetic	94
	control and diabetic treated rats under direct	
	and indirect stimulation.	

List of tables

Table No.	Name	Page
Table 1	Fasting and postprandial serum glucose levels of normal, diabetic and diabetic rats treated with sildenafil	70
Table 2	Blood glycosylaed hemoglobin (HbA1c%), serum insulin level and HOMA-IR of normal control, diabetic and diabetic rats treated with sildenafil.	73
Table 3	Liver and muscle glycogen levels of normal, diabetic and diabetic rats treated with sildenafil.	77
Table 4	Lipid profile of normal, diabetic and diabetic rats treated with sildenafil.	81
Table 5	Serum TNF-α, IL-1β and IL-6 of normal control, diabetic and diabetic rats treated with sildenafil.	84
	Liver MDA and GSH of normal, diabetic and diabetic rats treated with sildenafil.	87
	Liver SOD and GPx of normal, diabetic and diabetic rats treated with sildenafil.	90
Tahle 8	Effect of sildenafil on skeletal muscle contractility of normal, diabetic and diabetic rats treated with sildenafil.	

List of figures

Fig.	Name	Page
Figure 1	Schematic presentation of insulin signaling pathways	14
Figure 2	Beneficial and detrimental effects of NO.	33
Figure 3	Synthesis reaction of nitric oxide.	37
Figure 4	Effect of sildenafil on fasting and	71
	postprandial blood glucose levels of normal	
	control, diabetic and diabetic treated rats.	
Figure 5	Effect of sildenafil on serum insulin	74
	concentration.	
Figure 6	Effect of sildenafil on HOMA-IR.	75
Figure 7	Effect of sildenafil on HbA1c%.	75
Figure 8	Effect of sildenafil on liver glycogen content.	78
Figure 9	Effect of sildenafil on muscle glycogen content.	78
Figure 10	Effect of sildenafil on lipid profile.	82
Figure 11	Serum TNF- α , IL-1 β and IL-6 of normal control, diabetic and diabetic rats treated with sildenafil.	85
Figure 12	Liver MDA of normal control, diabetic and	88
	diabetic treated rats.	
Figure 13	Liver GSH of normal control, diabetic and	88
	diabetic treated rats.	
Figure 14	Liver SOD of normal control, diabetic and	91
	diabetic treated rats.	

Figure 15:	Liver GPx of normal control, diabetic and	91
	diabetic treated rats.	
Figure 16	Diaphragm contractility index of normal	94
	control, diabetic and diabetic treated rats under direct and indirect stimulation.	

INTRODUCTION

The incidence and prevalence of diabetes mellitus (DM), and its attendant complications are rising to epidemic levels (Zimmet et al., 2001; Deshpande et al., 2008). Diabetes mellitus is a chronic disease of disturbed carbohydrate, fat, and protein metabolism and can result in significant progressive and permanent physical disability (Gregg et al., 2002; Turcotte and Fisher, 2008). In 2002, DM was reported as the sixth leading cause of death, and the risk of mortality for individuals with DM is twice that of individuals of the same age without DM (National Diabetes Fact Sheet, 2005). Several comorbid conditions are related to and accompany DM, including coronary heart disease (Gregg et al., 2002; Von Korff et al., 2005), obesity (Gregg et al., 2002), arthritis, stroke (Gregg et al., 2000), depression (Von Korff et al., 2005), and visual impairments (Gregg et al., 2002) and have been identified as contributors to DM-related disability (Park et al., 2006 and 2007).

The full extent of the combined effects of obesity and DM and their respective complications on alterations in body composition and muscular function has not been thoroughly explored. The major tissue affected by disturbances in glucose metabolism is skeletal muscle, and deficits in metabolic signaling in this tissue contribute to systemic insulin resistance (Wei et al., 2008; Turcotte and Fisher, 2008).

Approximately 60% to 70% of people with DM have mild to severe forms of nervous system disease (National Diabetes Fact Sheet, 2005). It has been estimated that nearly 50% of all people with DM will develop somatic sensory, motor, or autonomic peripheral neuropathy (PN) or a combination of these types of neuropathy 25 years or later after diagnosis. Individuals with DM and PN develop rapid muscle weakness and motor dysfunction (Andersen et al., 1997). There are only a few studies examining skeletal muscle strength in diabetes, thus the current study was designed to evaluate the effect of sildenafil citrate, a phosphodiesterase 5 inhibitor, on skeletal muscle contractility via direct and indirect stimulation in high fat diet/streptozotocin diabetic rats.